An interventional study of Vitamin D in Vitamin D Deficiency, sponsored by Sheba Medical Center. Completed at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-18.
Sponsored by Sheba Medical Center · Not applicable, Interventional, and Treatment
Vitamin D is part of the regular treatment regimen among patients after heart transplantation. Due to potential drug-drug interaction between vitamin D and everolmus, these patients are in increased risk for increased everolimus metabolism, potentially leading to under- immunosupression.
post heart transplantation patients treated with everolimus will be screened for vitamin D levels. Patients defined as deficient will be treated with vitamin D with close and intensive monitoring everolimus levels, adjusting oral daily dose to maintain therapeutic levels.
784 studies on the registry are indexed under Vitamin D Deficiency; 61 are open to participants now.
This study's enrollment of 11 is below the median of 77 across 574 interventional studies indexed under Vitamin D Deficiency.
Browse Vitamin D Deficiency studies →Sheba Medical Center is the lead sponsor of 677 studies on the registry; 63 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Heart transplanted patients treated with everolimus
Exclusion Criteria:
-
Vitamin D supplementation and close everolimus trough levels monitoring with oral dose adjustments
Dietary Supplement: Vitamin D
Regular and routine monitoring
Oral daily vitamin D
Oral daily everolimus dose change
Time frame: 8 weeks
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vitamin D